Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors

Figure 2

Comparison of aa70 mutations in the HCV core region and the rate of HCVRNA becoming negative during the course of treatment. Compared with the wild type, among the patients of aa70 mutations, there were fewer patients in whom HCVRNA had become negative during the course of treatment.